Market Research Report
Self-Administered Ambulatory Subcutaneous Infusion Systems
|Published by||Greystone Research Associates||Product code||929359|
Delivery time: 1-2 business days
|Self-Administered Ambulatory Subcutaneous Infusion Systems|
|Published: March 24, 2020||Content info:||
Converging Factors Driving the Growth of Subcutaneous Infusion
As currently formulated, a significant number of therapeutic drugs require dosage volumes or possess viscosities well in excess of the upper range for traditional subcutaneous delivery. These drugs are currently delivered via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are a major driver of the energy behind small form factor subcutaneous infusion systems. As the adoption of and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. This dramatic shift in healthcare delivery is creating a need for devices that mask an underlying layer of complexity via design initiatives that are patient-friendly.